FDA Benzocaine Safety Alert Also Targets Pain From Public Citizen Complaint
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
FDA is considering forcing off the market OTC benzocaine oral care products for treating infant teething pain, seven years after acknowledging the ingredient's link to a rare but potentially fatal condition, methemoglobinemia, and raising the possibility of requiring label changes.